Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Introduction

When a member presents with fatigue, brain fog, migraines, sleep disturbance, and post-exertional malaise (PEM) — but without the classic gastrointestinal, respiratory, or dermatologic features of mast cell activation — it raises an important clinical pattern: neuro-dominant mast cell activation syndrome (MCAS) overlapping with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

This phenotype is increasingly recognized in the literature. A 2025 study by Weinstock, Afrin, and colleagues surveying 553 MCAS clients found that neuropsychiatric manifestations — including chronic fatigue, cognitive dysfunction, migraine-like headaches, and insomnia — were among the most prevalent symptoms reported, often exceeding traditional allergic presentations (Weinstock et al., 2025). Theoharides et al. have demonstrated that mast cells located in the meninges are directly implicated in migraine pathophysiology through neuropeptide release, vasodilation, and trigeminal sensitization (Theoharides et al., 2005).

For these folks, the question is rarely whether to intervene — it is how to sequence interventions in a system that is exquisitely sensitive to change.

Low-Dose Naltrexone as the Foundational Anchor

Low-dose naltrexone (LDN) has emerged as a cornerstone intervention in ME/CFS. A retrospective analysis of 218 ME/CFS clients treated with LDN (3.0–4.5 mg/day) reported a 73.9% positive treatment response, with improvements in vigilance, alertness, and both physical and cognitive performance (Polo, 2019). Mechanistically, LDN modulates the mu-opioid receptor, restoring function of the Transient Receptor Potential Melastatin 3 (TRPM3) ion channel in natural killer cells — a pathway increasingly implicated in ME/CFS pathophysiology (Cabanas et al., 2021; Löhn & Wirth, 2024).

When a client reports that migraines have resolved and sleep is improving on LDN — even at ultra-low doses such as 0.1 mg — that represents a meaningful signal. It confirms the system is responsive and provides a stable baseline from which to consider additional interventions.

The Decision-Making Framework: One Variable, Lowest Risk First

For the sensitive client — the "canary" — sequencing decisions must be governed by a set of principles that prioritize signal clarity and minimize the risk of confounding or adverse reactions.

1. Use Existing Clues as Functional Provocation Data

If a someone reports that cetirizine rapidly clears brain fog, that is a functional provocation test. It provides indirect evidence that histamine or mast cell mediators are driving that specific neurological symptom. This observation is clinically valuable regardless of what intervention comes next, and it narrows the mechanistic hypothesis.

2. Risk-Stratify Each Option

Sulforaphane is a food-derived Nrf2 activator and isothiocyanate compound found in cruciferous vegetables, particularly broccoli sprouts. In vitro studies have demonstrated that sulforaphane directly inhibits mast cell-mediated inflammatory mediators — including TSLP, TNF-α, IL-1β, IL-6, and IL-8 — through suppression of the caspase-1/NF-κB/MAPK signaling pathways (Jeon et al., 2020). Separate research has shown its capacity to reduce neuroinflammation through Nrf2/HO-1 activation and NF-κB inhibition in microglial cells (Subedi et al., 2019). As a review in Immunology & Cell Biology summarized, sulforaphane acts as a negative regulator of NF-κB activation and cytokine release while simultaneously activating Nrf2-dependent cytoprotective pathways (Treasure et al., 2023).

The clinical downside risk in a sensitive client is generally limited to a transient detoxification-type flare rather than a pharmacological side effect. This makes it a reasonable low-risk first addition.

Ketotifen is an antihistamine with mast cell stabilizing properties that has gained attention in the MCAS, ME/CFS, and dysautonomia communities. A Phase 1 randomized controlled trial of ketotifen in fibromyalgia (2 mg twice daily for 8 weeks) explored its role in mast cell-driven pain; while the trial did not demonstrate statistically significant pain reduction at the studied dose, the authors noted the favorable safety profile and the biological rationale for higher-dose studies (Ang et al., 2015). Ketotifen crosses the blood-brain barrier, which makes it mechanistically compelling for neuro-dominant MCAS presentations, but also introduces the possibility of CNS side effects including sedation and, in some sensitive clients, paradoxical activation.

D-Phenylalanine (DPLA) is a naturally occurring amino acid hypothesized to act as an enkephalinase inhibitor, reducing the degradation of endogenous enkephalins and thereby, in theory, supporting the body's endogenous analgesia system (Ehrenpreis, 1982). It is worth noting that the clinical evidence is mixed: a double-blind crossover trial in chronic pain clients found D-phenylalanine no more effective than placebo (Walsh et al., 1986). Mechanistically it is of interest alongside LDN, as both engage opioid receptor pathways — but introducing DPLA while LDN is still being optimized risks obscuring the independent contribution of each intervention.

Methylene blue (MB) is a mitochondrial electron carrier with emerging interest in neuroinflammatory and neurodegenerative conditions. Given its CNS activity and more complex pharmacological profile, it is generally best reserved for later sequencing after a cleaner baseline has been established.

3. Apply the Canary Rule

If a one's mast cell activation presents predominantly through neurological symptoms — migraines, brain fog, fatigue, visual disturbance, sleep disruption — then the nervous system is the primary mast cell target organ. This means any intervention with direct CNS activity (ketotifen, methylene blue) warrants more clinical runway and a more clearly established baseline before introduction. Agents that work upstream on inflammatory signaling without crossing the blood-brain barrier as their primary mechanism (sulforaphane) carry inherently less neurological risk in this population.

4. Sequence for Signal Clarity

Based on these principles, a rational sequencing approach for the neuro-dominant ME/CFS-MCAS canary might follow this logic:

First: Allow LDN to continue building. At 0.1 mg with only three months of exposure, there is likely additional clinical response yet to emerge. LDN's effects on TRPM3 channel function, immune modulation, and neuroinflammation may continue to develop over 6–12 months.

Second: Introduce sulforaphane as the lowest-risk next addition. Begin at a conservative dose, maintain for at least two weeks to establish a response baseline, and document any changes in brain fog, energy, or other tracked symptoms.

Third: Consider ketotifen after a stable sulforaphane baseline is established. Its mast cell stabilizing properties and blood-brain barrier penetrance make it mechanistically appropriate for the neuro-dominant phenotype, but it should be introduced as a clearly isolated variable.

Fourth: DPLA and methylene blue can be deferred. DPLA muddies the LDN signal; MB introduces too many variables at this stage.

Conclusion

The art of clinical sequencing in sensitive ME/CFS-MCAS clients is not about finding the single best intervention — it is about preserving the ability to read the system's responses. One variable at a time, lowest risk first, slowest titration tolerable, with enough observation time to distinguish signal from noise. This framework applies whether the client is working independently with their clinician or navigating a complex multi-system protocol.

This is not medical advice — it is a framework for thinking about sequencing decisions in the context of a sensitive neuroimmune system. Individual clinical decisions should always be made in partnership with a qualified healthcare provider.

References

Ang DC, Hilligoss J, Stump T. Mast cell stabilizer (ketotifen) in fibromyalgia: Phase 1 randomized controlled clinical trial. Clin J Pain. 2015;31(9):836-842.

Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: Role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Front Immunol. 2021;12:687806.

Ehrenpreis S. D-phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application. Acupunct Electrother Res. 1982;7(2-3):157-172.

Jeon M, Lee J, Lee HK, Cho SJ, Lim JH, Choi Y, Pak S, Jeong HJ. Sulforaphane mitigates mast cell-mediated allergic inflammatory reactions in in silico simulation and in vitro models. Immunopharmacol Immunotoxicol. 2020;42(2):74-83.

Löhn M, Wirth KJ. Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone. J Transl Med. 2024;22(1):630.

Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomed Health Behav. 2019;7(4):207-217.

Subedi L, Cho K, Park YU, Choi HJ, Kim SY. Sulforaphane-enriched broccoli sprouts pretreated by pulsed electric fields reduces neuroinflammation and ameliorates scopolamine-induced amnesia in mouse brain through its antioxidant ability via Nrf2-HO-1 activation. Oxid Med Cell Longev. 2019;2019:3549274.

Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005;49(1):65-76.

Treasure K, Harris J, Williamson G. Exploring the anti-inflammatory activity of sulforaphane. Immunol Cell Biol. 2023;101(9):805-828.

Walsh NE, Ramamurthy S, Schoenfeld L, Hoffman J. Analgesic effectiveness of D-phenylalanine in chronic pain patients. Arch Phys Med Rehabil. 1986;67(7):436-439.

Weinstock LB, Afrin LB, Reiersen AM, Brook J, Blitshteyn S, Ehrlich G, Schofield JR, Kinsella L, Kaufman D, Dempsey T, Molderings GJ. Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain Behav Immun Health. 2025;48:101048.

About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified Preventive Medicine physician with over 20 years of clinical experience in integrative and functional medicine. He completed fellowship training as an Osher Fellow under Dr. Andrew Weil at the University of Arizona and holds additional certifications in medical acupuncture (UCLA) and Integrative & Holistic Medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of three books — including the LDN Primer and a clinical LDN textbook — and over 20 peer-reviewed articles.

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com